Lepu Biopharma Co., Ltd. (HKG:2157)

Lepu Biopharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	401.29	426.02	669.4	155.17	402.87
Short-Term Investments	11.08	8.78	8.81	59.07	27.87
Trading Asset Securities	63.63	63.63	-	-	330.66
Cash & Short-Term Investments	475.99	498.43	678.2	214.24	761.4
Cash Growth	-4.50%	-26.51%	216.57%	-71.86%	297.77%
Accounts Receivable	45.82	37.8	3.04	-	-
Other Receivables	35.97	17.37	22.3	0.07	0.12
Receivables	81.79	55.17	25.34	0.07	0.12
Inventory	22.79	29.41	24.06	24.18	19.57
Prepaid Expenses	63.89	89.36	81.62	73.34	62.27
Other Current Assets	1.05	4.78	3.58	2.3	-
Total Current Assets	645.51	677.15	812.8	314.13	843.35
Property, Plant & Equipment	1,051	1,087	1,039	978.44	770.04
Long-Term Investments	114.07	126.69	122.39	137.97	160.29
Goodwill	52.64	52.64	52.64	52.64	52.64
Other Intangible Assets	350.29	369.93	398.18	422.45	445.29
Long-Term Deferred Charges	32.33	11.65	-	-	-
Other Long-Term Assets	34.82	59.01	104.1	176.43	152.01
Total Assets	2,281	2,384	2,529	2,082	2,424
Accounts Payable	236.14	207.61	166.13	158.82	42.45
Accrued Expenses	34.48	32.88	32.51	23.96	20.65
Short-Term Debt	-	-	329.63	40.41	-
Current Portion of Long-Term Debt	538.41	434.3	30.36	20	-
Current Portion of Leases	44.36	28.34	37.17	22.91	22.28
Current Income Taxes Payable	16.91	1	1.51	1.94	0.91
Current Unearned Revenue	0.91	-	-	4	2
Other Current Liabilities	172.31	195.43	246.49	277.02	293.94
Total Current Liabilities	1,044	899.56	843.79	549.06	382.22
Long-Term Debt	255.94	260	290.06	232.47	147.27
Long-Term Leases	11.46	24.18	3.09	19.48	33.53
Long-Term Unearned Revenue	18.02	12	12	12	12
Long-Term Deferred Tax Liabilities	37.69	37.69	37.69	37.69	37.69
Other Long-Term Liabilities	232.27	262.17	441.79	384.29	309.18
Total Liabilities	1,599	1,496	1,628	1,235	921.89
Common Stock	1,711	1,659	1,659	1,532	1,493
Additional Paid-In Capital	2,578	2,420	2,420	1,842	1,620
Retained Earnings	-2,765	-2,354	-2,331	-1,642	-631.44
Comprehensive Income & Other	-820.49	-828.8	-847.04	-894.2	-1,008
Total Common Equity	702.83	896.91	900.76	836.71	1,474
Minority Interest	-21.02	-8.21	-	10.37	28.21
Shareholders' Equity	681.8	888.7	900.76	847.08	1,502
Total Liabilities & Equity	2,281	2,384	2,529	2,082	2,424
Total Debt	850.16	746.82	690.3	335.26	203.08
Net Cash (Debt)	-374.17	-248.4	-12.1	-121.03	558.32
Net Cash Per Share	-0.22	-0.15	-0.01	-0.08	0.49
Filing Date Shares Outstanding	1,711	1,659	1,659	1,659	1,532
Total Common Shares Outstanding	1,711	1,659	1,659	1,532	1,532
Working Capital	-398.01	-222.42	-30.99	-234.93	461.13
Book Value Per Share	0.41	0.54	0.54	0.55	0.96
Tangible Book Value	299.9	474.34	449.95	361.62	975.59
Tangible Book Value Per Share	0.18	0.29	0.27	0.24	0.64
Buildings	660.23	45.55	45.55	-	-
Machinery	378.64	365.38	246.16	195.06	175.87
Construction In Progress	22.38	628.15	661.64	633.35	386.98
Leasehold Improvements	118.91	106.03	105.71	102.42	89.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.